Cervical Cancer Elimination Is Dependent on Women's Self-Tests for Primary Human Papillomavirus Testing Triaged by Methylation Status-Reference-Cited by-同舟云学术

Cervical Cancer Elimination Is Dependent on Women's Self-Tests for Primary Human Papillomavirus Testing Triaged by Methylation Status

Published:2022-09-10 Issue:26 Volume:40 Page:3003-3005
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Harper Diane M.¹^ORCID

Affiliation:

1. University of Michigan, Michigan Institute of Clinical and Health Research, Departments of Family Medicine, Obstetrics and Gynecology, Women's and Gender Studies, Ann Arbor, MI

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.00609

Reference26 articles.

1. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials

2. Maternal HPV-antibodies and seroconversion to HPV in children during the first 3 years of life

3. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Performance of DNA methylation analysis in the detection of high-grade cervical intraepithelial neoplasia or worse (CIN3+): a cross-sectional study;Infectious Agents and Cancer;2023-11-29

2. Design and Analytical Evaluation of a Rapid Plasma Screening Assay for Circulating Human Papillomavirus DNA via Thermostable Enzyme Chemistries;Analytical Chemistry;2023-07-13

3. Te Ara Waiora–Implementing human papillomavirus (HPV) primary testing to prevent cervical cancer in Aotearoa New Zealand: A protocol for a non-inferiority trial;PLOS ONE;2023-03-23

4. Cervical Cancer Stage at Diagnosis and Survival among Women ≥65 Years in California;Cancer Epidemiology, Biomarkers & Prevention;2023-01-09